Journal: SpringerPlus

Article Title: Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1Êyear experience.

PMID/MRN: 27733977

Publication Date: 2016-11-02

Abstract:

There is no global consensus for the optimal management of HCC. Most of patients at the time of diagnosis are not candidate for potentially curative therapy. The study aimed to evaluate the efficacy of low dose capecitabine combined with sorafenib in subset of Egyptian HCV patients presented with advanced HCC unfit for surgical or locoregional therapies. 15 patients with advanced HCC, unfit for surgical or locoregional intervention, with PSÊ<2 recieved Capecitabine 500Êmg/day with sorafeneb 200Êmg twice daily till normalization of AFP then the treatment was modified to capecitabine 250Êmg every other day and sorafenib 400Êmg once daily. They were followed every 3Êmonths for size, number of focal masses and AFP. 30 patients were selected as a control group, they received supportive therapy (nÊ=Ê15) or sorafenib only (nÊ=Ê15). After 10Êmonths of therapy, 6 patients showed complete response (40Ê%) with complete recanalization of portal vein (nÊ=Ê2) and treatment was stopped and the others (nÊ=Ê4) showed partial portal vein recanalization so, treatment is continued till now. 1 patient (6.7Ê%) showed recurrence of the disease and died after 1Êmonth, 8 patients showed partial response (53.3Ê%) and still on treatment. The control groups showed a highly significant reduction in survival when compared to patients who received capecitabine and sorafenib (12.9ʱÊ2.1, 7.9ʱÊ0.9, 4.5ʱÊ1.3Êmonths, pÊ=Ê0.000). Combined low dose capecitabine and sorafenib proved to be safe with low toxicity profile and deserves further attention as a convenient, outpatient-based chemotherapy in patients with advanced HCC.